St. Jude to acquire CardioMEMS following FDA approval of device

Reuters

St. Jude Medical said on Wednesday it plans to exercise its option to buy the shares of CardioMEMS it does not already own for $375 million following news the Food and Drug Administration has approved CardioMEMS' wireless heart device.

Letter
to the
Editor

Send us a letter

Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

Recommended for You
U.S. Food and Drug Administration (FDA)
Upcoming FDA draft on pulse oximetry's racial bias draws questions
Most Popular
1
UnitedHealthcare CEO’s killing unleashes rage against insurers
2
Kaiser-backed Risant Health completes Cone Health acquisition
3
What to expect in the primary care market in 2030
4
UnitedHealthcare CEO Brian Thompson's killing shocks industry
5
Police: UnitedHealthcare CEO shooting a 'brazen, targeted attack'